HilleVax, Inc.
HLVXNASDAQHealthcare
$2.09
$-0.01(-0.48%)
Market Cap$104762381
P/E Ratio—
52W High$2.17
52W Low$1.34
HilleVax, Inc. (HLVX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HLVX · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 6, 2025EPS Actual
-$0.52
Est. -$0.15 · -246.7%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 6, 2025
After Market Close
▼ Miss EPS
HLVX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.15 | -$0.52 | -246.7% | — | — | — |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.14 | -$0.11 | +21.4% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.37 | -$0.12 | +67.6% | — | — | — |
| ▼ Q1 FY2025 | Mar 28, 2025 | -$0.33 | -$0.35 | -6.1% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.42 | -$0.52 | -23.8% | — | — | — |
| ▼ Q3 FY2024 | Aug 8, 2024 | -$0.78 | -$0.83 | -6.4% | — | — | — |
| ▼ Q2 FY2024 | May 9, 2024 | -$0.84 | -$0.97 | -15.5% | — | — | — |
| ▲ Q1 FY2024 | Mar 20, 2024 | -$0.83 | -$0.78 | +6.0% | $0.00B | — | — |
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.52
EPS Est.
-$0.15
EPS Surpr.
-246.7%
Revenue
—
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.14
EPS Surpr.
+21.4%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.37
EPS Surpr.
+67.6%
Revenue
—
Q1 FY2025
Mar 28, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.33
EPS Surpr.
-6.1%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.52
EPS Est.
-$0.42
EPS Surpr.
-23.8%
Revenue
—
Q3 FY2024
Aug 8, 2024Miss
EPS Actual
-$0.83
EPS Est.
-$0.78
EPS Surpr.
-6.4%
Revenue
—
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$0.97
EPS Est.
-$0.84
EPS Surpr.
-15.5%
Revenue
—
Q1 FY2024
Mar 20, 2024Beat
EPS Actual
-$0.78
EPS Est.
-$0.83
EPS Surpr.
+6.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q3 FY2025 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q2 FY2025 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q1 FY2025 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q4 FY2024 | $-0.46 | $-0.33 | $-0.27 | 3 |
| Q3 FY2024 | $-0.42 | $-0.42 | $-0.42 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 6, 2025 | -246.7% | $2.09 | — | — |
| ▲ Q3 FY2025 | Aug 6, 2025 | +21.4% | $2.05 | $2.05 | +0.00% |
| ▲ Q2 FY2025 | May 8, 2025 | +67.6% | $1.85 | $1.91 | +3.24% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -6.1% | $1.61 | $1.59 | -1.24% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -23.8% | $1.96 | $1.94 | -1.02% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -6.4% | $1.61 | $1.66 | +3.11% |
| ▼ Q2 FY2024 | May 9, 2024 | -15.5% | $13.48 | $13.99 | +3.78% |
| ▲ Q1 FY2024 | Mar 20, 2024 | +6.0% | $17.43 | $16.11 | -7.57% |
Q4 FY2025—
Report Date
Nov 6, 2025
EPS Beat/Miss
-246.7%
Price Before
$2.09
Price After
—
Q3 FY2025+0.00%
Report Date
Aug 6, 2025
EPS Beat/Miss
+21.4%
Price Before
$2.05
Price After
$2.05
Q2 FY2025+3.24%
Report Date
May 8, 2025
EPS Beat/Miss
+67.6%
Price Before
$1.85
Price After
$1.91
Q1 FY2025-1.24%
Report Date
Mar 28, 2025
EPS Beat/Miss
-6.1%
Price Before
$1.61
Price After
$1.59
Q4 FY2024-1.02%
Report Date
Nov 7, 2024
EPS Beat/Miss
-23.8%
Price Before
$1.96
Price After
$1.94
Q3 FY2024+3.11%
Report Date
Aug 8, 2024
EPS Beat/Miss
-6.4%
Price Before
$1.61
Price After
$1.66
Q2 FY2024+3.78%
Report Date
May 9, 2024
EPS Beat/Miss
-15.5%
Price Before
$13.48
Price After
$13.99
Q1 FY2024-7.57%
Report Date
Mar 20, 2024
EPS Beat/Miss
+6.0%
Price Before
$17.43
Price After
$16.11
Avg Beat Reaction-1.44%
Avg Miss Reaction+1.16%
Beat Rate3 / 8 quarters
Largest Move-7.57% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HLVX ends December
HilleVax, Inc. (HLVX) most recently reported earnings on November 6, 2025 for Q4 FY2025, posting EPS of $-0.52 — missing the analyst consensus of $-0.15 by -246.7%. The next HLVX earnings date is expected around September 1, 2026.
Each quarter, investors track HLVX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HLVX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HLVX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HLVX earnings · 5 questionsHilleVax, Inc.'s next earnings report is expected around September 1, 2026. HLVX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HLVX historically reports after market close (AMC).
HLVX earnings datewhen is HLVX earningsHLVX next earnings datewhen does HLVX report earningsHLVX earnings calendar
▸ Source: FMP · HilleVax, Inc. SEC filings · US GAAP · HilleVax, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026